SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

Pepe is trending as community members highlight bullish price action and speculate about future growth potential. Conversations mention the potential for significant gains and the coin's strong community support. Some users are drawing comparisons to other meme coins on Solana, suggesting a broader interest in the sector.

"What's Updog?" is a Community Led token.

UpDog

$UPDOG.X is trending as community members highlight its long-term development on the Solana blockchain and its listing on the Jupiter Strict List. The community is actively using the project's namesake punchline and comparing it to other popular meme coins like $DOGE.X and $SHIB.X, suggesting it could be the next big meme coin.

TOSHI

TOSHI.X is trending as the community rallies around the meme coin, anticipating significant gains and a potential Binance listing soon. Bullish sentiment is fueled by recent listings, the coin's association with Coinbase, and its status as the 'face of base'. Traders are closely watching for a breakout, with some suggesting a coordinated buy to propel the price higher.

Nyvo is a cutting-edge platform that allows anyone to create fully functional decentralized applications (dApps) using simple natural language prompts. In other words, users describe the app they want in plain English, and Nyvo’s AI-driven engine automatically generates both the on-chain smart contract backend and the web-based frontend, delivering a live blockchain application within minutes. This “prompt-to-dApp” approach dramatically lowers the barriers to Web3 development by removing the need to write code or navigate complex developer tools.The result is that developers, entrepreneurs, and even non-technical users can go from an idea to a deployed dApp faster and easier than ever before.

Nyvo

Nyvo ($NYVO.X) is trending as social media buzz points to strong chart momentum and a potential breakout. The crypto community is signaling a 'buy now' opportunity, anticipating a rapid price increase. Conversations evoke a sense of urgency, suggesting a 'rocket' is about to launch.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community anticipates upcoming revenue figures and discusses treasury mechanics.  Enthusiasm is building around its real-world asset (RWA) adoption and potential for significant growth. Some users are also discussing potential integrations with other tokens.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

$GASS.X is trending as community members highlight its potential, drawing comparisons to $PEPE.X due to its connection with creator Matt Furie, and some are pointing to a recent listing. Community members are actively discussing holding for long-term gains, emphasizing accumulation during dips, and expressing excitement about the project's future.

JFB Construction Holdings - Ordinary Shares - Class A

JFB is trending due to the formation of its board and after-hours trading activity. However, some investors are concerned about a dilutive deal involving warrants without a lock-up period. The community is actively discussing the potential impact of these factors on the stock's price.

Blockchain-on-Blockchain (BOB) is a new blockchain built on top of another blockchain called ICP. It's like a special layer on an existing system. BOB creates a secure digital record book that uses ICP's network for safety. BOB uses a system called 'proof-of-on-chain-work': You deploy your own smart contract (canister) at bob.fun. This program solves math problems (hashes). Main computers (mother nodes) give out these problems. Miners solve the problems and tell the mother node. If correct, the mother node adds a new block to the blockchain. The winning miner gets BOB tokens as a reward.

$BOB.X is gaining attention, with community members highlighting its potential for a squeeze and comparing it favorably to other cryptocurrencies. The upcoming halving event and its association with $ICP.X are key points of discussion, with some suggesting it could be the next $BTC.X. Community sentiment is very bullish.

Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the developing of oncology and immuno-oncology therapies. Its pipeline includes CLN-978, CLN-619, Zipalertinib CLN-081/TAS6417, CLN-049, and CLN-617. The company was founded by Patrick A. Baeuerle on September 15, 2016 and is headquartered in Cambridge, MA.

Cullinan Therapeutics Inc

Cullinan Oncology Inc

Cullinan Oncology is trending due to analyst upgrades and upcoming presentations at the ASCO and other medical conferences, highlighting data related to their cancer treatment pipeline. Community members are actively discussing the company's valuation, pipeline potential, and recent insider trading activity. A recent analysis comparing CGEM to a competitor, BDTX, is also circulating.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

$RAGE.X is trending with community members expressing bullish sentiment and urging others to buy in before a potential surge. Conversations highlight the token's strong community and potential for significant gains, with some drawing comparisons to other successful meme coins. The broader discussion includes the potential for 'short squeeze' and the presence of 'big names' within the community.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

India’s healthcare sector has received a boost from the latest round of Goods and Services Tax (GST) reform.The government has lowered GST across several products and services in the healthcare basket, making treatments and coverage more affordable while creating volume opportunities for companies.What Got CheaperHealth and life insurance, previously taxed at 18%, will now attract no GST at all. Thermometers have been reduced from 18% to 5%. Medical-grade oxygen, diagnostic kits, reagents, glucometers, and test strips have all seen rates cut from 12% to 5%.&nbsp;Corrective spectacles also shift from 12% to 5%. Finkhoz said these cuts translate into lower costs for consumers and stronger demand across healthcare services and products.Technical ViewSEBI-registered platform&nbsp;<a href="https://stocktwits.com/Finkhoz">Finkhoz</a> said the Nifty Healthcare index is consolidating just below the key resistance zone of 14,800–15,000, noting that the index is forming an inverted head-and-shoulders pattern, with the neckline around the same zone.&nbsp;<stembedurl>https://stocktwits.com/Finkhoz/message/628102110</stembedurl>A breakout above 14,800–15,000, if supported by volume, could trigger a rally toward 15,800–16,200, while strong support is placed at 14,000.Stocks To WatchPrivate hospitals, such as Apollo Hospitals and Fortis Healthcare, could see an increase in demand as wider insurance coverage makes it easier for patients to choose private care.&nbsp;Diagnostic players like Metropolis Healthcare and Dr Lal Pathlabs are also likely to benefit, with cheaper kits expected to drive more people toward regular testing and higher volumes.&nbsp;Medical device makers such as Poly Medicure are positioned to benefit from lower GST on devices and reagents. Optical businesses, including Titan Company’s Titan Eye+, may also see a lift from cheaper spectacles.&nbsp;Insurance players like HDFC Life, ICICI Prudential, and SBI Life could be major winners, with tax-free health insurance described by Finkhoz as a “game-changer.”Analyst ViewFinkhoz said the GST cuts are not only about affordability but also about broadening access to healthcare.&nbsp;More insurance adoption, cheaper diagnostics, and lower device costs are expected to create steady growth opportunities across healthcare and insurance. “For investors, healthcare just got its booster shot,” the analyst concluded.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Healthcare Stocks Get A GST Boost: Index Nears Breakout; Bull Run Likely In Apollo, Fortis, Dr Lal, Poly Medicure 

The analyst said the GST cut expands access to care while opening steady opportunities for companies in the sector.

Equity

Dr Lal PathLabs evicted from Chandigarh shop over rental dues

Dr. Lal PathLabs was evicted from a Sector 11-D shop due to over Rs 1.50 crore in unpaid rent. A court order, issued on July 4, led to the property's handover to the owners. The lab had failed to pay rent since June 2024, despite an earlier order to vacate.

Metropolis, Dr Lal PathLabs shares dip up to 3% as Amazon enters diagnostic market

Diagnostic stocks like Metropolis Healthcare and Dr Lal PathLabs fell up to 3% on June 23 as Amazon launched home diagnostic services, increasing competition in India's diagnostics market valued at $15 billion.

Imane Khelif is man: Leaked Lal PathLabs' report unveils the dark reality of the Olympic gold medalist

Algerian Olympic boxing champion Imane Khelif is at the centre of a global controversy after a leaked medical report from India’s Dr Lal PathLabs revealed she has male chromosomes. The 2023 test resurfaced following her gold medal win at the 2024 Paris Olympics. Critics, including fellow athletes, raised concerns about fairness and safety in women’s boxing. While World Boxing calls for genetic verification, the IOC dismissed the test results, claiming misinformation. The issue spotlights unresolved tensions between inclusivity and integrity in elite women’s sport.

Dr. Lal Pathlabs Ltd has moved from a long-term downtrend towards a potential uptrend using Wyckoff structure analysis, according to SEBI-registered analyst Harshit Goel.<stembedurl>https://stocktwits.com/valuesense/message/614703232</stembedurl>According to Goel, the stock ended its accumulation stage after May 2022's selling climax, which featured high volume and no downside continuation signaling hidden demand.&nbsp;At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/LALPATHLAB.NSE">Dr. Lal Pathlabs shares</a> were trading at ₹2,795.00, down 8.45% year-to-date.The consistent appearance of higher lows, diminished market volatility, and shrinking supply volumes indicated institutional buying activity.After surpassing important resistance levels at ₹2,630 and ₹2,757, supported by strong volume, the stock showed a “sign of strength” rally, Goel said.&nbsp;He added that the price maintained its position above these levels with reduced selling pressure, which indicates a markup phase starting.Goel has a positive outlook over the medium term while protecting his position with a stop-loss threshold at ₹2,350.&nbsp;The stock shows primary support within the range of ₹2,380 to ₹2,757, while the next resistance point stands at ₹2,995, according to the analyst.The technical analysis comes after Dr. Lal PathLabs posted strong consolidated results, with net sales increasing to ₹603 crore in&nbsp;the March quarter from ₹545 crore a year ago.The company's quarterly net profit&nbsp;soared 83.2%&nbsp;to&nbsp; ₹154.80 crore&nbsp;from a year earlier.Management highlighted volume expansion as&nbsp;its primary strategy by selecting not to increase prices currently.The company anticipates FY26 growth between 11% and 12% due to an increase in volume while maintaining steady revenue per patient.Dr. Lal Pathlabs sees a reduction in margins by 100 basis points to approximately 27% because of investments in geographic expansion and digital initiatives along with talent acquisition and marketing.The stock has declined 8.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Lal Pathlabs Shows Signs Of Rebound After Long Downtrend: SEBI RA Harshit Goel

The analyst advises a medium-term bullish stance with a stop-loss at ₹2,350 amid signs of institutional demand and reduced selling pressure.

Dr Lal Path Labs Q4 Results: Co beats quarterly profit view on medical testing boom

Dr Lal Path Labs, India's largest diagnostics firm by revenue, reported fourth-quarter profit above expectations on Friday as strong demand for its bundled test packages lifted growth amid rising health awareness in the country.

Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. It also involves in providing diagnostic and healthcare tests and services. The company was founded by S. K. Lal in 1949 and is headquartered in Gurgaon, India.

Current Price	3,190.10
Prev Close	3,231.50
Open	3,230.20
Dividend Yield	0.97%
50-Day Moving Average	3,233.66
Beta	0.11
Avg. Volume	124,166.26
PE Ratio	51.88

52-Week High	3,653.95
52-Week Low	2,293.55
Market Capitalization	266.9B
EPS (Annual)	58.48
Price to Book	12.26
Revenue Per Employee	4.64M
Enterprise Value/EBITDA	N/A

LALPATHLAB.NSE
Dr. Lal PathLabs Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest LALPATHLAB.NSE News

LALPATHLAB.NSE Dr. Lal PathLabs Ltd.